- All sections
- C - Chemistry; metallurgy
- C12N - Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
- C12N 15/13 - Immunoglobulins
Patent holdings for IPC class C12N 15/13
Total number of patents in this class: 6075
10-year publication summary
232
|
317
|
233
|
266
|
367
|
548
|
626
|
674
|
527
|
119
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Chugai Seiyaku Kabushiki Kaisha | 1259 |
103 |
Genentech, Inc. | 3742 |
70 |
National Research Council of Canada | 1545 |
66 |
Shanghai Hengrui Pharmaceutical Co., Ltd. | 588 |
66 |
Amgen Inc. | 3779 |
59 |
Jiangsu Hengrui Medicine Co., Ltd. | 780 |
55 |
Regeneron Pharmaceuticals, Inc. | 3650 |
55 |
Daiichi Sankyo Company, Limited | 1829 |
51 |
F. Hoffmann-La Roche AG | 7958 |
47 |
Innovent Biologics (Suzhou) Co., Ltd. | 210 |
47 |
Janssen Biotech, Inc. | 1347 |
45 |
Zymeworks Inc. | 234 |
45 |
Novartis AG | 11238 |
39 |
Wuxi Biologics (Shanghai) Co. Ltd. | 117 |
32 |
The University of British Columbia | 1432 |
31 |
Akeso Biopharma, Inc. | 80 |
30 |
Pfizer Inc. | 3322 |
27 |
Immatics Biotechnologies GmbH | 1144 |
27 |
The Regents of the University of California | 18943 |
26 |
Astellas Pharma Inc. | 1145 |
25 |
Other owners | 5129 |